Where do we stand in the treatment of Parkinson's disease?

Journal of Neurology

Volumn 254, Issue SUPPL. 5, 2007, Pages 13-18

  Mizuno, Yoshikuni ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Guidelines; Neuroprotection; Parkinson's disease; Treatment

Indexed keywords

3,4 DIHYDROXY 6 FLUORO DEXTRO,LEVO PHENYLALANINE; 3BETA (4 IODOPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; CARBIDOPA; CREATINE; DOPAMINE RECEPTOR STIMULATING AGENT; DOPAMINE TRANSPORTER; LEVODOPA; MINOCYCLINE; MONOAMINE OXIDASE B INHIBITOR; PLACEBO; PRAMIPEXOLE; RADIOPHARMACEUTICAL AGENT; RASAGILINE; ROPINIROLE; SELEGILINE; UBIDECARENONE; UNCLASSIFIED DRUG;

CLINICAL PRACTICE; CONFERENCE PAPER; CORPUS STRIATUM; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG TOLERANCE; DYSKINESIA; HUMAN; LONG TERM CARE; NEUROPROTECTION; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT DURATION; TREATMENT OUTCOME; UNITED STATES; UNSPECIFIED SIDE EFFECT;

EID: 34548740291     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-007-5003-9     Document Type: Conference Paper

References (22)

1. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24:197-211
2. Guttman M, Stewart D, Hussey D, Wilson A, Houle S, Kish S (2001) Influence of L-dopa and pramipexole on striatal dopamine transporter in early PD. Neurology 56:1559-1564
3. Holloway RG, Shoulson I, Fahn S, Kieburtz K, Lang A, Marek K, McDermott M, Seibyl J, Weiner W, Musch B, Kamp C, Welsh M, Shinaman A, Pahwa R, Barclay L, Hubble J, LeWitt P, Miyasaki J, Suchowersky O, Stacy M, Russell DS, Ford B, Hammerstad J, Riley D, Standaert D, Wooten F, Factor S, Jankovic J, Atassi F, Kurlan R, Panisset M, Rajput A, Rodnitzky R, Shults C, Petsinger G, Waters C, Pfeiffer R, Biglan K, Borchert L, Montgomery A, Sutherland L, Weeks C, DeAngelis M, Sime E, Wood S, Pantella C, Harrigan M, Fussell B, Dillon S, Alexander-Brown B, Rainey P, Tennis M, Rost-Ruffner E, Brown D, Evans S, Berry D, Hall J, Shirley T, Dobson J, Fontaine D, Pfeiffer B, Brocht A, Bennett S, Daigneault S, Hodgeman K, O'Connell C, Ross T, Richard K, Watts A; Parkinson Study Group (2004) Pramipexole vs L-dopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 61:1044-1053
4. 123I]beta-CIT. Mov Disord 14:436-442
5. NINDS NET-PD Investigators (2006) A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology 66:664-671
6. Nurmi E, Bergman J, Eskola O, Solin O, Hinkka SM, Sonninen P, Rinne JQ (2000) Reproducibility and effect of L-dopa on dopamine transporter function measurements: a [F-18]CFT PET study. J Cereb Blood Flow Metab 20:1604-1609
7. Olanow CW, Hauser RA, Gauger L, Malapira T, Koller W, Hubble J, Bushenbark K, Lilienfeld D, Esterlitz J (1995) The effect of deprenyl and L-dopa on the progression of Parkinson's disease. Ann Neurol 38:771-777
8. Palhagen S, Heinonen E, Hagglund J, Kaugesaar T, Maki-Ikola O, Palm R; Swedish Parkinson Study Group (2006) Selegiline slows the progression of the symptoms of Parkinson's disease. Neurology 66:1200-1206
9. Parkinson Study Group (1989) Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 321:1364-1371
10. Parkinson Study Group (1993) Effect of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 328:176-183
11. Parkinson Study Group (1996) Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring L-dopa.Ann Neurol 39:29-36
12. Parkinson Study Group (1996) Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring L-dopa. Ann Neurol 39:37-45
13. Parkinson Study Group (2000) Pramipexole vs L-dopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA 284: 1931-1938
14. Parkinson Study Group (2002) Dopamine transporter brain imaging to assess the effects of pramipexole vs L-dopa on Parkinson disease progression JAMA 287:1653-1661
15. Parkinson Study Group (2004) A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 61:561-566
16. Parkinson Study Group (2004) L-dopa and the progression of Parkinson's disease. N Engl J Med 351:2498-2508
17. Rascol O, Brooks DJ, Korczyn AD,De Deyn PP, Clarke CE, Lang AE (2000) A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or L-dopa. New Engl J Med 342:1484-1491
18. Ravina BM, Fagan SC, Hart RG, Hovinga CA, Murphy DD, Dawson TM, Marler JR (2003) Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment. Neurology 60:1234-1240
19. Rinne UK, Bracco F, Chouza C, Dupont E, Gershanik O, Marti Masso JF, Montastruc JL, Marsden CD (1998) Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind L-dopa controlled trial. The PKDS009 Study Group. Drugs 55(Suppl 1):23-30
20. 10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol 59:1541-1550
21. Thomas A, Iacono D, Luciano AL, Amellino K, Di Iorio A, Onofrj M (2004) Duration of amantadine benefit on dyskinesia of severe Parkinson's disease. J Neurol Neurosurg Psychiatry 75:141-143
22. Whone AL, Remy P, Davis MR, Sabolek M, Nahmias C, Stoessl AJ, Watts RL, Brooks DJ (2002) The REAL-PET study: slower progression in early Parkinson's disease treated with ropinirole compared with L-dopa. Neurology 58(Suppl 3):A82-A83